Sidoti Csr Has Positive Outlook for Kamada FY2025 Earnings

Kamada Ltd. (NASDAQ:KMDA) – Research analysts at Sidoti Csr increased their FY2025 earnings per share estimates for shares of Kamada in a report issued on Thursday, October 2nd. Sidoti Csr analyst J. Sidoti now forecasts that the biotechnology company will earn $0.33 per share for the year, up from their prior forecast of $0.28. The consensus estimate for Kamada’s current full-year earnings is $0.23 per share. Sidoti Csr also issued estimates for Kamada’s Q1 2027 earnings at $0.08 EPS, Q2 2027 earnings at $0.11 EPS, Q3 2027 earnings at $0.12 EPS and FY2027 earnings at $0.42 EPS.

Separately, Weiss Ratings reissued a “buy (b-)” rating on shares of Kamada in a research note on Saturday, September 27th. Three research analysts have rated the stock with a Buy rating and one has issued a Hold rating to the company. According to MarketBeat, Kamada has an average rating of “Moderate Buy” and a consensus target price of $13.00.

Kamada Stock Performance

NASDAQ KMDA opened at $6.65 on Monday. The business has a 50 day simple moving average of $7.04 and a 200 day simple moving average of $7.00. Kamada has a 52-week low of $5.18 and a 52-week high of $9.15. The stock has a market cap of $382.44 million, a price-to-earnings ratio of 19.56, a PEG ratio of 0.68 and a beta of 0.84.

Kamada (NASDAQ:KMDA) last announced its quarterly earnings results on Wednesday, August 13th. The biotechnology company reported $0.13 EPS for the quarter, beating analysts’ consensus estimates of $0.09 by $0.04. Kamada had a return on equity of 7.41% and a net margin of 11.22%.The company had revenue of $44.75 million during the quarter, compared to analysts’ expectations of $158.59 million. Kamada has set its FY 2025 guidance at EPS.

Hedge Funds Weigh In On Kamada

A number of large investors have recently bought and sold shares of the company. Huntleigh Advisors Inc. boosted its position in Kamada by 3.9% during the 2nd quarter. Huntleigh Advisors Inc. now owns 135,776 shares of the biotechnology company’s stock worth $1,052,000 after acquiring an additional 5,151 shares during the last quarter. Acadian Asset Management LLC boosted its position in Kamada by 3.1% during the 2nd quarter. Acadian Asset Management LLC now owns 263,556 shares of the biotechnology company’s stock worth $2,053,000 after acquiring an additional 7,925 shares during the last quarter. Trexquant Investment LP acquired a new position in Kamada during the 1st quarter worth approximately $82,000. NewEdge Advisors LLC boosted its position in Kamada by 119.9% during the 1st quarter. NewEdge Advisors LLC now owns 51,661 shares of the biotechnology company’s stock worth $341,000 after acquiring an additional 28,165 shares during the last quarter. Finally, Jump Financial LLC acquired a new stake in shares of Kamada in the 2nd quarter valued at approximately $219,000. Institutional investors and hedge funds own 20.38% of the company’s stock.

Kamada Company Profile

Kamada Ltd. manufactures and sells plasma-derived protein therapeutics. Its commercial products include KAMRAB/KEDRAB for treating prophylaxis of rabies; CYTOGAM for Prophylaxis of Cytomegalovirus disease in kidney, lung, liver, pancreas, heart, and heart/lung transplants; VARIZIG for post exposure prophylaxis of varicella; WINRHO SDF for immune thrombocytopenic purpura and suppression of rhesus isoimmunization; HEPAGAM B for prevention of hepatitis B recurrence liver transplants and post-exposure prophylaxis; GLASSIA for intravenous AATD; KAMRHO (D) IM for prophylaxis of hemolytic disease of newborns; KAMRHO (D) IV for immune thermobocytopunic purpura; and Echis coloratus and Vipera palaestinae Antiserum for the treatment of snake bite.